JPMorgan lowered the firm’s price target on Immunovant (IMVT) to $37 from $40 and keeps an Overweight rating on the shares. The firm updated the company’s model post earnings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant’s Promising Pipeline and Strong Financial Position Signal a Buy Rating
- Immunovant’s Promising Advances in Graves’ Disease Treatment Drive Buy Rating
- Immunovant Reports Progress and Financial Results
- Immunovant’s Strategic Advancements and Clinical Progress Justify Buy Rating
- Immunovant price target lowered to $57 from $58 at Citi